Contact Congress about S. 2658: Medication Affordability and Patent Integrity Act
Drug and biologic makers would have to tell the FDA and patent office the same key facts. If they hide or leave out required patent information, it could weaken their case in a patent lawsuit. The bill may affect when cheaper generic or biosimilar medicines can compete, but it does not lower prices by itself.
Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.
Medication Affordability and Patent Integrity Act is a Senate bill in committee. The latest recorded action: Committee on Health, Education, Labor, and Pensions. Hearings held.
Latest action on S. 2658: Committee on Health, Education, Labor, and Pensions. Hearings held.
Who this affects: This bill mainly affects brand-name drug and biologic companies, especially those seeking FDA approval while also trying to protect patents. It also affects generic and biosimilar makers that may challenge those patents. Patients, insurers, and pharmacies could feel indirect effects if the bill changes when lower-cost competitors enter the market.
Why this matters: Drug patents can help decide how long lower-cost medicines must wait to compete. This bill tries to stop companies from telling the FDA one thing and the patent office another. It could make patent records clearer and make some patents easier to challenge. But the price effect is uncertain, because courts, agencies, and companies would decide how much the new rules matter in practice.
Key provisions in S. 2658
- Drug and biologic companies would have to certify key patent-related information to the FDA. They would have to say it matches what they gave the U.S. Patent and Trademark Office.
- Those companies would have to send the patent office certain FDA information about the same patents. They would also have to send related FDA responses.
- The sharing rule would cover only information the patent office says matters to patentability. That means information that could affect whether a patent should be granted or kept, such as test data, manufacturing controls, and prior art statements.
- An applicable patent would include patents and patent applications for the drug or biologic itself. It would also include its formula, its approved use, how it is made, and other patents agencies later add by rule.
- New FDA applications filed after the bill becomes law would face the full rules. Older applications would face narrower rules, mainly for patents issued later or communications made later.
How Modern Action helps you take action on S. 2658
You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.
Questions people ask about S. 2658
- What is S. 2658?
- Drug and biologic makers would have to tell the FDA and patent office the same key facts. If they hide or leave out required patent information, it could weaken their case in a patent lawsuit. The bill may affect when cheaper generic or biosimilar medicines can compete, but it does not lower prices by itself.
- How do I support or oppose S. 2658?
- Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.
- Who should I contact about S. 2658?
- Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.
- Can Modern Action explain S. 2658 before I act?
- Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.
